Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Mar 26

PMID 35337152

Authors

Jessica Cusato

Lucio Boglione

Amedeo De Nicolo

Gian Paolo Caviglia

Simone Mornese Pinna

Alessia Ciancio

Giulia Troshina

Antonina Smedile

Miriam Antonucci

Valeria Avataneo

Alice Palermiti

Jacopo Mula

Alessandra Manca

Giuseppe Cariti

Marco Cantu

Giorgio Maria Saracco

Giovanni Di Perri

Antonio DAvolio

Affiliations

Soon will be listed here.

Abstract

Sofosbuvir (SOF) is an HCV NS5B polymerase inhibitor, and GS-331007 is its major metabolite. The aim of this study was to investigate whether clinical and pharmacological factors could influence GS-331007 intracellular (IC) concentrations in peripheral blood mononuclear cells (PBMCs) associated with a sustained virological response in patients treated with SOF and ribavirin (RBV). Drug levels were analyzed using liquid chromatography at different days of therapy, whereas variants in genes encoding transporters and nuclear factors were investigated using real-time PCR. This study enrolled 245 patients treated with SOF; 245 samples were analyzed for pharmacogenetics and 50 were analyzed for IC pharmacokinetics. The GS-331007 IC concentration at 30 days was associated with its plasma concentration determinate at 30, 60 and 90 days of SOF-therapy and with daclatasvir concentrations at 7 days of therapy. No genetic polymorphism affected IC exposure. In linear multivariate analysis, ledipasvir treatment, baseline albumin and estimated glomerular filtration rate were significant predictors of IC exposure. This study presents data on an IC evaluation in a cohort of patients treated with SOF, also considering pharmacogenetics. These results could be useful for regions where SOF-RBV treatment is considered the standard of care; moreover, they could further deepen the knowledge of IC exposure for similar drugs in the future.

References

Rodriguez Gil F, Perez Garrido I . Sofosbuvir antiviral therapy in HCV patients with severe renal failure. Gastroenterol Hepatol. 2016; 40(2):85-86. DOI: 10.1016/j.gastrohep.2015.12.013. View

Gonzalez-Grande R, Jimenez-Perez M, Gonzalez Arjona C, Mostazo Torres J . New approaches in the treatment of hepatitis C. World J Gastroenterol. 2016; 22(4):1421-32. PMC: 4721977. DOI: 10.3748/wjg.v22.i4.1421. View

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

Lawitz E, Gane E . Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 369(7):678-9. DOI: 10.1056/NEJMc1307641. View

Schinazi R, Halfon P, Marcellin P, Asselah T . HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2013; 34 Suppl 1:69-78. PMC: 7737539. DOI: 10.1111/liv.12423. View

Rivero-Juarez A, Brieva T, Frias M, Rivero A . Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol. 2018; 14(9):901-910. DOI: 10.1080/17425255.2018.1506765. View

King J, Dutta S, Cohen D, Podsadecki T, Ding B, Awni W . Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir. Antimicrob Agents Chemother. 2015; 60(2):855-61. PMC: 4750706. DOI: 10.1128/AAC.01913-15. View

Cusato J, De Nicolo A, Boglione L, Favata F, Ariaudo A, Mornese Pinna S . Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. J Antimicrob Chemother. 2018; 73(6):1659-1664. DOI: 10.1093/jac/dky053. View

Babusis D, Curry M, Kirby B, Park Y, Murakami E, Wang T . Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. Antimicrob Agents Chemother. 2018; 62(5). PMC: 5923114. DOI: 10.1128/AAC.02587-17. View

10.

Ascoli G, Domenici E, Bertucci C . Drug binding to human serum albumin: abridged review of results obtained with high-performance liquid chromatography and circular dichroism. Chirality. 2006; 18(9):667-79. DOI: 10.1002/chir.20301. View

11.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet A . Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin Pharmacokinet. 2009; 49(1):17-45. DOI: 10.2165/11318110-000000000-00000. View

12.

Poordad F, Schiff E, Vierling J, Landis C, Fontana R, Yang R . Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5):1493-505. PMC: 5069651. DOI: 10.1002/hep.28446. View

13.

Ahmed B, Munir B, Ghaffar A, Yameen M, Jalal F, Farooq M . Pharmacokinetics profile of serum and cellular Sofosbuvir along with its concentration effect analysis in HCV patients receiving Sofosbuvir and Ribavirin. Pak J Pharm Sci. 2019; 32(3 (Supplementary)):1269-1274. View

14.

Cusato J, Allegra S, De Nicolo A, Boglione L, Fatiguso G, Abdi A . Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. J Pharm Pharm Sci. 2015; 18(2):171-6. DOI: 10.18433/j3dk6t. View

15.

Ariaudo A, Favata F, De Nicolo A, Simiele M, Paglietti L, Boglione L . A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. J Pharm Biomed Anal. 2016; 125:369-75. DOI: 10.1016/j.jpba.2016.04.031. View

16.

Feld J, Maan R, Zeuzem S, Kuo A, Nelson D, Di Bisceglie A . Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clin Infect Dis. 2016; 63(6):776-783. PMC: 4996139. DOI: 10.1093/cid/ciw387. View

17.

Gutierrez J, Carrion A, Avalos D, OBrien C, Martin P, Bhamidimarri K . Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015; 21(6):823-30. PMC: 6658191. DOI: 10.1002/lt.24126. View

18.

Ivanyuk A, Livio F, Biollaz J, Buclin T . Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet. 2017; 56(8):825-892. DOI: 10.1007/s40262-017-0506-8. View

19.

German P, Mathias A, Brainard D, Kearney B . Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. Clin Pharmacokinet. 2016; 55(11):1337-1351. DOI: 10.1007/s40262-016-0397-0. View

20.

De Nicolo A, Agnesod D, Simiele M, Rigano D, Adriani A, Canaparo R . UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptoguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. J Pharm Biomed Anal. 2014; 98:271-8. DOI: 10.1016/j.jpba.2014.05.040. View